Contact us
- Level 1, 75 Talavera Road Wallumattagal Campus
- Macquarie University NSW 2109
- E: macquarie.medicalschool@mq.edu.au
Our biobank enables research in areas of unmet clinical need
Learn about the biobankCancer and cell biology research at Macquarie University is a multidisciplinary program that brings together talented research scientists and clinicians.
Our research teams collaborate across cutting-edge research, clinical trials, and personalised medicine, ensuring that research discoveries are translated into better treatments and support for cancer patients.
Our research spans multiple cancer types, including melanoma, lung cancer and colorectal cancer. Our research involves:
Our research spans three core groups.
This research is focused on uncovering the contrasting impacts of antibiotic use in individuals with lung cancer and harnessing the benefits of the human microbiome in cancer care.
The aim is to improve lung cancer therapies by integrating targeted antibiotic use with standard treatments and creating microbiome-based biomarker tools for use in the clinic.
Group lead: Professor Maija Kohonen-Corish
The Precision Cancer Therapy research group investigates the genetic mechanisms and cellular programs that shape treatment response and resistance in cancer.
We are committed to developing blood-based biomarkers (liquid biopsies) that guide clinical decision-making. Our goal is to refine treatment strategies and improve patient outcomes.
Group lead: Professor Helen Rizos
Our research group specialises in advanced multi-proteomic technologies (protein chemistry) to explore the biology and aetiology of cancer, with a primary focus on colorectal cancer (CRC).
We are dedicated to discovering novel protein biosignatures from blood and tissue samples, aiming to enhance early detection of CRC and pinpoint high-risk tumour recurrence in stage II CRC.
Our multidisciplinary team comprises experts from Macquarie University and esteemed collaborators from other universities and hospitals, including:
The team works together to advance cancer research and improve patient outcomes.
Group leads: